Citations (116)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Giulia Ciotti, Giovanni Marconi, Alessandra Sperotto, Maria B Giannini, Michele Gottardi & Giovanni Martinelli. (2023) Biological therapy in elderly patients with acute myeloid leukemia. Expert Opinion on Biological Therapy 23:2, pages 175-194.
Read now
Read now
Adam J DiPippo, Nathaniel R Wilson & Naveen Pemmaraju. (2021) Targeting CD123 in BPDCN: an emerging field. Expert Review of Hematology 14:11, pages 993-1004.
Read now
Read now
Mohammad Reza Khirehgesh, Jafar Sharifi, Fatemeh Safari & Bahman Akbari. (2021) Immunotoxins and nanobody-based immunotoxins: review and update. Journal of Drug Targeting 29:8, pages 848-862.
Read now
Read now
Manuel Ricardo Espinoza-Gutarra, Steven D Green, Joshua F. Zeidner & Heiko Konig. (2021) CD123-targeted therapy in acute myeloid leukemia. Expert Review of Hematology 14:6, pages 561-576.
Read now
Read now
Ibrahim Aldoss, Mary Clark, Joo Y Song & Vinod Pullarkat. (2020) Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia. Human Vaccines & Immunotherapeutics 16:10, pages 2341-2348.
Read now
Read now
Sophia S. Lee, Deborah McCue & Naveen Pemmaraju. (2020) Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm. Expert Review of Anticancer Therapy 20:7, pages 543-550.
Read now
Read now
Mansour Alfayez, Marina Konopleva & Naveen Pemmaraju. (2020) Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). Expert Opinion on Biological Therapy 20:2, pages 115-123.
Read now
Read now
Minas P. Economides, Deborah McCue, Andrew A. Lane & Naveen Pemmaraju. (2019) Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm. Expert Review of Clinical Pharmacology 12:10, pages 941-946.
Read now
Read now
Challice L. Bonifant, Mireya Paulina Velasquez & Stephen Gottschalk. (2018) Advances in immunotherapy for pediatric acute myeloid leukemia. Expert Opinion on Biological Therapy 18:1, pages 51-63.
Read now
Read now
Meng Li, Zeng-Shan Liu, Xi-Lin Liu, Qi Hui, Shi-Ying Lu, Lin-Lin Qu, Yan-Song Li, Yu Zhou, Hong-Lin Ren & Pan Hu. (2017) Clinical targeting recombinant immunotoxins for cancer therapy. OncoTargets and Therapy 10, pages 3645-3665.
Read now
Read now
Sagun Parakh, Adam C. Parslow, Hui K. Gan & Andrew M. Scott. (2016) Antibody-mediated delivery of therapeutics for cancer therapy. Expert Opinion on Drug Delivery 13:3, pages 401-419.
Read now
Read now
Yanjun Zhang, Rong Liu, Dongmei Fan, Rizan Shi, Ming Yang, Qingfang Miao, Zhao-Qun Deng, Jun Qian, Yongsu Zhen, Dongsheng Xiong & Jianxiang Wang. (2015) The novel structure make LDM effectively remove CD123+ AML stem cells in combination with interleukin 3. Cancer Biology & Therapy 16:10, pages 1514-1525.
Read now
Read now
J. A. O'Brien & D. A. Rizzieri. (2013) Leukemic Stem Cells: A Review. Cancer Investigation 31:4, pages 215-220.
Read now
Read now
Gail J Roboz & Monica Guzman. (2009) Acute myeloid leukemia stem cells: seek and destroy. Expert Review of Hematology 2:6, pages 663-672.
Read now
Read now
Johannes Kohlschütter, Stefan Michelfelder & Martin Trepel. (2008) Drug delivery in acute myeloid leukemia. Expert Opinion on Drug Delivery 5:6, pages 653-663.
Read now
Read now
Articles from other publishers (101)
Juan Peng, Shaolong He, Xingcheng Yang, Liang Huang & Jia Wei. (2023) Plasmacytoid dendritic cell expansion in myeloid neoplasms: A novel distinct subset of myeloid neoplasm?. Critical Reviews in Oncology/Hematology 192, pages 104186.
Crossref
Crossref
Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Antonino Neri, Annalisa Imovilli, Fortunato Morabito, Ernesto Vigna & Massimo Gentile. (2023) Tagraxofusp in myeloid malignancies. Hematological Oncology.
Crossref
Crossref
Edoardo Peroni, Maria Luigia Randi, Antonio Rosato & Stefano Cagnin. (2023) Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment. Journal of Experimental & Clinical Cancer Research 42:1.
Crossref
Crossref
Evan C. Chen & Jacqueline S. Garcia. (2023) Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies. Acta Haematologica, pages 1-1.
Crossref
Crossref
Branko Cuglievan, Jeremy Connors, Jiasen He, Sajad Khazal, Sireesha Yedururi, Julia Dai, Sofia Garces, Andres E. Quesada, Michael Roth, Miriam Garcia, David McCall, Amber Gibson, Dristhi Ragoonanan, Demetrios Petropoulos, Priti Tewari, Cesar Nunez, Kris M. Mahadeo, Sarah K. Tasian, Adam J. Lamble, Anna Pawlowska, Danielle Hammond, Abhishek Maiti, Fadi G. Haddad, Jayatsu Senapati, Naval Daver, Naseema Gangat, Marina Konopleva, Soheil Meshinchi & Naveen Pemmaraju. (2023) Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia 37:9, pages 1767-1778.
Crossref
Crossref
Weizhou Yue & Jie Shen. (2023) Local Delivery Strategies for Peptides and Proteins into the CNS: Status Quo, Challenges, and Future Perspectives. Pharmaceuticals 16:6, pages 810.
Crossref
Crossref
Elvira Pelosi, Germana Castelli & Ugo Testa. (2023) CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm. International Journal of Molecular Sciences 24:3, pages 2718.
Crossref
Crossref
Harshita Pant, Timothy R. Hercus, Damon J. Tumes, Kwok Ho Yip, Michael W. Parker, Catherine M. Owczarek, Angel F. Lopez & David P. Huston. (2023) Translating the biology of β common receptor-engaging cytokines into clinical medicine. Journal of Allergy and Clinical Immunology 151:2, pages 324-344.
Crossref
Crossref
Lauren Pommert & Katherine Tarlock. (2022) The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies. Hematology 2022:1, pages 603-610.
Crossref
Crossref
Muhammad Jameel Mughal & Hang Fai Kwok. (2022) Multidimensional role of bacteria in cancer: Mechanisms insight, diagnostic, preventive and therapeutic potential. Seminars in Cancer Biology 86, pages 1026-1044.
Crossref
Crossref
Naveen Pemmaraju, Kendra L. Sweet, Anthony S. Stein, Eunice S. Wang, David A. Rizzieri, Sumithira Vasu, Todd L. Rosenblat, Christopher L. Brooks, Nassir Habboubi, Tariq I. Mughal, Hagop Kantarjian, Marina Konopleva & Andrew A. Lane. (2022) Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. Journal of Clinical Oncology 40:26, pages 3032-3036.
Crossref
Crossref
Belay Zeleke Sibuh, Rekha Gahtori, Noura Al-Dayan, Kumud Pant, Bahareh Farasati Far, Asrar Ahmad Malik, Ashish Kumar Gupta, Soumi Sadhu, Sushil Dohare & Piyush Kumar Gupta. (2022) Emerging trends in immunotoxin targeting cancer stem cells. Toxicology in Vitro 83, pages 105417.
Crossref
Crossref
Sanjive Qazi & Fatih M. Uckun. (2022) Augmented Expression of the IL3RA/CD123 Gene in MLL/KMT2A-Rearranged Pediatric AML and Infant ALL. Onco 2:3, pages 245-263.
Crossref
Crossref
David J. Flavell & Sopsamorn U. Flavell. (2022) Plant-Derived Type I Ribosome Inactivating Protein-Based Targeted Toxins: A Review of the Clinical Experience. Toxins 14:8, pages 563.
Crossref
Crossref
Linus Angenendt, Jan-Henrik Mikesch & Christoph Schliemann. (2022) Emerging antibody-based therapies for the treatment of acute myeloid leukemia. Cancer Treatment Reviews 108, pages 102409.
Crossref
Crossref
Elodie Bôle-Richard, Naveen Pemmaraju, Blandine Caël, Etienne Daguindau & Andrew A. Lane. (2022) CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers 14:9, pages 2287.
Crossref
Crossref
Fabio Andreozzi, Fulvio Massaro, Sebastian Wittnebel, Chloé Spilleboudt, Philippe Lewalle & Adriano Salaroli. (2022) New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy. International Journal of Molecular Sciences 23:7, pages 3887.
Crossref
Crossref
Yasmin Abaza & Amir T. Fathi. (2022) Monoclonal Antibodies in Acute Myeloid Leukemia—Are We There Yet?. The Cancer Journal 28:1, pages 37-42.
Crossref
Crossref
Dima Abla, Miguel R. Abboud, Dolly Noun, Nidale Tarek & Naveen Pemmaraju. (2022) Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review.. Leukemia Research Reports 17, pages 100313.
Crossref
Crossref
Kieran D. Sahasrabudhe, Audrey M. Sigmund & Bhavana Bhatnagar. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
41
.
Faroogh Marofi, Heshu Sulaiman Rahman, Zaid Mahdi Jaber Al-Obaidi, Abduladheem Turki Jalil, Walid Kamal Abdelbasset, Wanich Suksatan, Aleksei Evgenievich Dorofeev, Navid Shomali, Max Stanley Chartrand, Yashwant Pathak, Ali Hassanzadeh, Behzad Baradaran, Majid Ahmadi, Hossein Saeedi, Safa Tahmasebi & Mostafa Jarahian. (2021) Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. Stem Cell Research & Therapy 12:1.
Crossref
Crossref
Ilias Christodoulou, Won Jin Ho, Andrew Marple, Jonas W Ravich, Ada Tam, Ruyan Rahnama, Adam Fearnow, Cambrynne Rietberg, Sean Yanik, Elena E Solomou, Ravi Varadhan, Michael A Koldobskiy & Challice L Bonifant. (2021) Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. Journal for ImmunoTherapy of Cancer 9:12, pages e003894.
Crossref
Crossref
Liang Fei Xu, Lan Shi, Shan Shan Zhang, Peng Sheng Ding, Fan Ma, Kai Di Song, Ping Qiang, Wen Jiao Chang, Yuan Yuan Dai, Yi De Mei & Xiao Ling Ma. (2021) LukS-PV Induces Apoptosis via the SET8-H4K20me1-PIK3CB Axis in Human Acute Myeloid Leukemia Cells. Frontiers in Oncology 11.
Crossref
Crossref
LaQuita M. Jones, Katherine Tarlock & Todd Cooper. (2021) Targeted Therapy in Pediatric AML: An Evolving Landscape. Pediatric Drugs 23:5, pages 485-497.
Crossref
Crossref
Fatih M. Uckun, Tara L. Lin, Alice S. Mims, Prapti Patel, Cynthia Lee, Anoush Shahidzadeh, Paul J. Shami, Elizabeth Cull, Christopher R. Cogle & Justin Watts. (2021) A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. Cancers 13:16, pages 4113.
Crossref
Crossref
Victor Pallarès, Yáiza Núñez, Laura Sánchez-García, Aïda Falgàs, Naroa Serna, Ugutz Unzueta, Alberto Gallardo, Lorena Alba-Castellón, Patricia Álamo, Jorge Sierra, Antonio Villaverde, Esther Vázquez, Isolda Casanova & Ramon Mangues. (2021) Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4. Journal of Controlled Release 335, pages 117-129.
Crossref
Crossref
Alessandro Isidori, Claudio Cerchione, Naval Daver, Courtney DiNardo, Guillermo Garcia-Manero, Marina Konopleva, Elias Jabbour, Farhad Ravandi, Tapan Kadia, Adolfo de la Fuente Burguera, Alessandra Romano, Federica Loscocco, Giuseppe Visani, Giovanni Martinelli, Hagop Kantarjian & Antonio Curti. (2021) Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Frontiers in Oncology 11.
Crossref
Crossref
Gilda Varricchi, Remo Poto, Gianni Marone & John T. Schroeder. (2021) IL-3 in the development and function of basophils. Seminars in Immunology 54, pages 101510.
Crossref
Crossref
Wenbin Xiao, Alexander Chan, Michael R. WaartsTanmay MishraYing Liu, Sheng F. Cai, Jinjuan YaoQi GaoRobert L. BowmanRichard P. KocheIsabelle S. CseteNicole L. DelGaudioAndriy Derkach, Jeeyeon BaikSophia Yanis, Christopher A. Famulare, Minal Patel, Maria E. ArcilaMaximilian StahlRaajit K. RampalMartin S. TallmanYanming Zhang, Ahmet Dogan, Aaron D. Goldberg, Mikhail RoshalRoss L. Levine. (2021)
Plasmacytoid dendritic cell expansion defines a distinct subset of
RUNX1
-mutated acute myeloid leukemia
. Blood 137:10, pages 1377-1391.
Crossref
Crossref
M. Knödler & J.F. Buyel. (2021) Plant-made immunotoxin building blocks: A roadmap for producing therapeutic antibody-toxin fusions. Biotechnology Advances 47, pages 107683.
Crossref
Crossref
Sangeetha Venugopal, Naval Daver & Farhad Ravandi. (2021) An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia. Current Hematologic Malignancy Reports 16:1, pages 89-96.
Crossref
Crossref
Delia Cangini, Paolo Silimbani, Alessandro Cafaro, Maria B. Giannini, Carla Masini, Andrea Ghelli Luserna Di Rorà, Giorgia Simonetti, Giovanni Martinelli & Claudio Cerchione. (2020) Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope. Minerva Medica 111:5.
Crossref
Crossref
Hanadi El Achi, Edouard Dupont, Shilpa Paul & Joseph D. Khoury. (2020) CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies. Cancers 12:11, pages 3087.
Crossref
Crossref
Y. B. Balzhanova & V. G. Savchenko. (2020) The role of interleukin-3 and its receptor in acute leukemia pathogenesis. Russian journal of hematology and transfusiology 65:3, pages 335-350.
Crossref
Crossref
Naveen Pemmaraju & Marina Konopleva. (2020) Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. Blood Advances 4:16, pages 4020-4027.
Crossref
Crossref
Yuxin Tan, Qiuji Wu & Fuling Zhou. (2020) Targeting acute myeloid leukemia stem cells: Current therapies in development and potential strategies with new dimensions. Critical Reviews in Oncology/Hematology 152, pages 102993.
Crossref
Crossref
Lukas M. Braun & Robert Zeiser. (2020) Immunotherapy in Myeloproliferative Diseases. Cells 9:6, pages 1559.
Crossref
Crossref
Mayumi Sugita & Monica L. Guzman. (2020) CD123 as a Therapeutic Target Against Malignant Stem Cells. Hematology/Oncology Clinics of North America 34:3, pages 553-564.
Crossref
Crossref
Steven D. Green & Heiko Konig. (2020) Treatment of Acute Myeloid Leukemia in the Era of Genomics—Achievements and Persisting Challenges. Frontiers in Genetics 11.
Crossref
Crossref
Minas P. Economides, David Rizzieri & Naveen Pemmaraju. (2019) Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Current Hematologic Malignancy Reports 14:6, pages 515-522.
Crossref
Crossref
Fatemeh Shafiee, Marc G. Aucoin & Ali Jahanian-Najafabadi. (2019) Targeted Diphtheria Toxin-Based Therapy: A Review Article. Frontiers in Microbiology 10.
Crossref
Crossref
Testa, Pelosi & Castelli. (2019) CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies. Cancers 11:9, pages 1358.
Crossref
Crossref
Stefania Zuppone, Maria Serena Fabbrini & Riccardo Vago. (2019) Hosts for Hostile Protein Production: The Challenge of Recombinant Immunotoxin Expression. Biomedicines 7:2, pages 38.
Crossref
Crossref
Naveen PemmarajuAndrew A. LaneKendra L. SweetAnthony S. SteinSumithira VasuWilliam BlumDavid A. RizzieriEunice S. WangMadeleine DuvicJ. Mark SloanSharon SpenceShay ShemeshChristopher L. BrooksJohn BalserIvan BergsteinJeffrey E. LancetHagop M. KantarjianMarina Konopleva. (2019) Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. New England Journal of Medicine 380:17, pages 1628-1637.
Crossref
Crossref
Yahiya Y. Syed. (2019) Tagraxofusp: First Global Approval. Drugs 79:5, pages 579-583.
Crossref
Crossref
Omar Alkharabsheh & Arthur E. Frankel. (2019) Clinical Activity and Tolerability of SL-401 (Tagraxofusp): Recombinant Diphtheria Toxin and Interleukin-3 in Hematologic Malignancies. Biomedicines 7:1, pages 6.
Crossref
Crossref
Minas P. Economides, Marina Konopleva & Naveen Pemmaraju. (2019) Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm. Therapeutic Advances in Hematology 10, pages 204062071987473.
Crossref
Crossref
Jinghua Wang, Siyu Chen, Wei Xiao, Wende Li, Liang Wang, Shuo Yang, Weida Wang, Liping Xu, Shuangye Liao, Wenjian Liu, Yang Wang, Nawei Liu, Jianeng Zhang, Xiaojun Xia, Tiebang Kang, Gong Chen, Xiuyu Cai, Han Yang, Xing Zhang, Yue Lu & Penghui Zhou. (2018) CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. Journal of Hematology & Oncology 11:1.
Crossref
Crossref
Timothy R. Hercus, Winnie L. T. Kan, Sophie E. Broughton, Denis Tvorogov, Hayley S. Ramshaw, Jarrod J. Sandow, Tracy L. Nero, Urmi Dhagat, Emma J. Thompson, Karen S. Cheung Tung Shing, Duncan R. McKenzie, Nicholas J. Wilson, Catherine M. Owczarek, Gino Vairo, Andrew D. Nash, Vinay Tergaonkar, Timothy Hughes, Paul G. Ekert, Michael S. Samuel, Claudine S. Bonder, Michele A. Grimbaldeston, Michael W. Parker & Angel F. Lopez. (2018) Role of the β Common (βc) Family of Cytokines in Health and Disease. Cold Spring Harbor Perspectives in Biology 10:6, pages a028514.
Crossref
Crossref
Sarah Tasian, Martin Bornhäuser & Sergio Rutella. (2018) Targeting Leukemia Stem Cells in the Bone Marrow Niche. Biomedicines 6:1, pages 22.
Crossref
Crossref
Sophie E. Broughton, Timothy R. Hercus, Tracy L. Nero, Winnie L. Kan, Emma F. Barry, Mara Dottore, Karen S. Cheung Tung Shing, Craig J. Morton, Urmi Dhagat, Matthew P. Hardy, Nicholas J. Wilson, Matthew T. Downton, Christine Schieber, Timothy P. Hughes, Angel F. Lopez & Michael W. Parker. (2018) A dual role for the N-terminal domain of the IL-3 receptor in cell signalling. Nature Communications 9:1.
Crossref
Crossref
Aaron M. Goodman, Tiffany N. Tanaka & Dan S. Kaufman. 2018. Early Phase Cancer Immunotherapy. Early Phase Cancer Immunotherapy
133
184
.
Xuefei Wang, Shile Huang & Ji-Long Chen. (2017) Understanding of leukemic stem cells and their clinical implications. Molecular Cancer 16:1.
Crossref
Crossref
David A. Sallman & Marco L. Davila. (2017) Is Disease-Specific Immunotherapy a Potential Reality for MDS?. Clinical Lymphoma Myeloma and Leukemia 17, pages S26-S30.
Crossref
Crossref
Robert C. BastJr.Jr., Michael R. Zalutsky & Arthur E. Frankel. 2016. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
23
.
Jill M. Sullivan & David A. Rizzieri. (2016) Treatment of blastic plasmacytoid dendritic cell neoplasm. Hematology 2016:1, pages 16-23.
Crossref
Crossref
Saar Gill. (2016) Chimeric antigen receptor T cell therapy in AML: How close are we?. Best Practice & Research Clinical Haematology 29:4, pages 329-333.
Crossref
Crossref
Radhika Thokala, Simon Olivares, Tiejuan Mi, Sourindra Maiti, Drew Deniger, Helen Huls, Hiroki Torikai, Harjeet Singh, Richard E. Champlin, Tamara Laskowski, George McNamara & Laurence J. N. Cooper. (2016) Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors. PLOS ONE 11:8, pages e0159477.
Crossref
Crossref
Jayaprakasam Madhumathi, Sithambaram Devilakshmi, Surapally Sridevi & Rama S. Verma. (2016) Immunotoxin therapy for hematologic malignancies: where are we heading?. Drug Discovery Today 21:2, pages 325-332.
Crossref
Crossref
Muneera Al-Hussaini, Michael P. Rettig, Julie K. Ritchey, Darja Karpova, Geoffrey L. Uy, Linda G. Eissenberg, Feng GaoWilliam C. Eades, Ezio Bonvini, Gurunadh R. Chichili, Paul A. Moore, Syd Johnson, Lynne Collins & John F. DiPersio. (2016) Targeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform. Blood 127:1, pages 122-131.
Crossref
Crossref
Maximilian Stahl, Tae Kon Kim & Amer M Zeidan. (2016) Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. World Journal of Stem Cells 8:10, pages 316.
Crossref
Crossref
Ofir Wolach & Richard M. Stone. 2015. Targeted Therapy in Translational Cancer Research. Targeted Therapy in Translational Cancer Research
89
100
.
Gurunadh R. ChichiliLing HuangHua LiSteve BurkeLeilei HeQin TangLinda JinSergey GorlatovValentina CiccaroneFrancine ChenScott KoenigMichele ShannonRalph AldersonPaul A. MooreSyd JohnsonEzio Bonvini. (2015) A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates. Science Translational Medicine 7:289.
Crossref
Crossref
Arseniy E. Yuzhalin & Anton G. Kutikhin. 2015. Interleukins in Cancer Biology. Interleukins in Cancer Biology
319
326
.
Arseniy E. Yuzhalin & Anton G. Kutikhin. 2015. Interleukins in Cancer Biology. Interleukins in Cancer Biology
91
116
.
Yan Shen, Qi Liu, Yun Luo, Ping Zhang, FengXia Bai, ShiDi Cheng & ShiFeng Lou. (2014) Enhancement of the cytotoxic activity of cytokine-induced killer cells transfected with IL3PE38KDEL gene against acute myeloid leukemia cells. Annals of Hematology 93:12, pages 2019-2028.
Crossref
Crossref
S J Busfield, M Biondo, M Wong, H S Ramshaw, E M Lee, S Ghosh, H Braley, C Panousis, A W Roberts, S Z He, D Thomas, L Fabri, G Vairo, R B Lock, A F Lopez & A D Nash. (2014) Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia 28:11, pages 2213-2221.
Crossref
Crossref
Samanta A. Mariani & Bruno Calabretta. (2014) Leukemia stem cells: Old concepts and new perspectives. Molecular Aspects of Medicine 39, pages 102-109.
Crossref
Crossref
Olga Frolova, Juliana Benito, Chris Brooks, Rui-Yu Wang, Borys Korchin, Eric K. Rowinsky, Jorge Cortes, Hagop Kantarjian, Michael Andreeff, Arthur E. Frankel & Marina Konopleva. (2014) SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. British Journal of Haematology 166:6, pages 862-874.
Crossref
Crossref
Arthur E. FrankelJung H. WooChul AhnNaveen PemmarajuBruno C. MedeirosHetty E. CarrawayOlga FrankfurtStephen J. FormanXuezhong A. YangMarina KonoplevaFrancine Garnache-Ottou, Fanny Angelot-Delettre, Christopher Brooks, Michael Szarek & Eric Rowinsky. (2014) Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood 124:3, pages 385-392.
Crossref
Crossref
Saar GillSarah K. Tasian, Marco Ruella, Olga Shestova, Yong Li, David L. PorterMartin CarrollGwenn Danet-DesnoyersJohn Scholler, Stephan A. Grupp, Carl H. June & Michael Kalos. (2014) Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells. Blood 123:15, pages 2343-2354.
Crossref
Crossref
Maria Cioch & Karolina Radomska. (2014) Białaczkowe komórki macierzyste. Acta Haematologica Polonica 45:2, pages 161-165.
Crossref
Crossref
Eva NievergallHayley S. Ramshaw, Agnes S. M. Yong, Mark Biondo, Samantha J. Busfield, Gino Vairo, Angel F. Lopez, Timothy P. HughesDeborah L. WhiteDevendra K. Hiwase. (2014) Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. Blood 123:8, pages 1218-1228.
Crossref
Crossref
Robin E. Gasiorowski, Georgina J. Clark, Kenneth Bradstock & Derek N. J. Hart. (2014) Antibody therapy for acute myeloid leukaemia. British Journal of Haematology 164:4, pages 481-495.
Crossref
Crossref
Robert J. Kreitman. 2014. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
569
584
.
Sarah Tettamanti, Chiara Francesca Magnani, Andrea Biondi & Ettore Biagi. (2013) Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors. Immunology Letters 155:1-2, pages 43-46.
Crossref
Crossref
J. Felipe Rico, Duane C. Hassane & Monica L. Guzman. (2013) Acute myelogenous leukemia stem cells: From Bench to Bedside. Cancer Letters 338:1, pages 4-9.
Crossref
Crossref
Sarah Tettamanti, Virna Marin, Irene Pizzitola, Chiara F. Magnani, Greta M. P. Giordano Attianese, Elisabetta Cribioli, Francesca Maltese, Stefania Galimberti, Angel F. Lopez, Andrea Biondi, Dominique Bonnet & Ettore Biagi. (2013) Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. British Journal of Haematology 161:3, pages 389-401.
Crossref
Crossref
Jung Hee Woo & Arthur Frankel. 2013. Fusion Protein Technologies for Biopharmaceuticals. Fusion Protein Technologies for Biopharmaceuticals
271
293
.
Nate Waldron & Daniel Vallera. (2013) An Old Idea Tackling a New Problem: Targeted Toxins Specific for Cancer Stem Cells. Antibodies 2:4, pages 82-92.
Crossref
Crossref
H. Joachim Deeg, David T. Bowen, Steven D. Gore, Torsten Haferlach, Michelle M. Le Beau & Charlotte NiemeyerSarah M. Greenblatt, H. Joachim Deeg & Stephen D. Nimer. 2013. Myelodysplastic Syndromes. Myelodysplastic Syndromes
73
84
.
S.-R. Kuo, L. Wong & J.-S. Liu. (2012) Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. Protein Engineering Design and Selection 25:10, pages 561-570.
Crossref
Crossref
Vu Duong & Jeffrey Lancet. 2012. Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics. Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics
315
348
.
David J. FitzGerald, Alan S. Wayne, Robert J. Kreitman & Ira Pastan. (2011) Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates. Cancer Research 71:20, pages 6300-6309.
Crossref
Crossref
Michael W. Becker & Craig T. Jordan. (2011) Leukemia stem cells in 2010: Current understanding and future directions. Blood Reviews 25:2, pages 75-81.
Crossref
Crossref
Christoph Stein, Ingo Schubert & Georg H. Fey. 2011. Bispecific Antibodies. Bispecific Antibodies
65
82
.
J Li, L Shi, X Zhang, X Kang, Y Wen, H Qian, Y Zhou, W Xu, Y Zhang, M Wu & Z Yin. (2010) Recombinant adenovirus IL-24-Bax promotes apoptosis of hepatocellular carcinoma cells in vitro and in vivo. Cancer Gene Therapy 17:11, pages 771-779.
Crossref
Crossref
Axel Schulenburg, Kira Brämswig, Harald Herrmann, Heidrun Karlic, Irina Mirkina, Rainer Hubmann, Sylvia Laffer, Brigitte Marian, Medhat Shehata, Clemens Krepler, Hubert Pehamberger, Thomas Grunt, Ulrich Jäger, Christoph C. Zielinski & Peter Valent. (2010) Neoplastic stem cells: Current concepts and clinical perspectives. Critical Reviews in Oncology/Hematology 76:2, pages 79-98.
Crossref
Crossref
Markus Kügler, Christoph Stein, Christian Kellner, Kristin Mentz, Domenica Saul, Michael Schwenkert, Ingo Schubert, Heiko Singer, Fuat Oduncu, Bernhard Stockmeyer, Andreas Mackensen & Georg H. Fey. (2010) A recombinant trispecific single‐chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. British Journal of Haematology 150:5, pages 574-586.
Crossref
Crossref
Richard T. Williams. (2010) IL3 receptor-dependent therapeutic targeting of BCR-ABL-driven lymphoid leukemias. Leukemia Research 34:8, pages 963-964.
Crossref
Crossref
Hyun Pyo Kim, Arthur E. Frankel & Donna E. Hogge. (2010) A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. Leukemia Research 34:8, pages 1035-1042.
Crossref
Crossref
P Fogar, F Navaglia, D Basso, C-F Zambon, L Moserle, S Indraccolo, A Stranges, E Greco, E Fadi, A Padoan, G Pantano, M C Sanzari, S Pedrazzoli, C Montecucco & M Plebani. (2009) Heat-induced transcription of diphtheria toxin A or its variants, CRM176 and CRM197: implications for pancreatic cancer gene therapy. Cancer Gene Therapy 17:1, pages 58-68.
Crossref
Crossref
Shu-Ru Kuo, Randall W. Alfano, Arthur E. Frankel & Jen-Sing Liu. (2009) Antibody Internalization after Cell Surface Antigen Binding is Critical for Immunotoxin Development. Bioconjugate Chemistry 20:10, pages 1975-1982.
Crossref
Crossref
Monica L. Guzman, Gerrit J. Schuurhuis & Craig T. Jordan. 2009. Cancer Stem Cells. Cancer Stem Cells
93
108
.
Roberta Riccioni, Daniela Diverio, Viviana Riti, Sonia Buffolino, Gualtiero Mariani, Alessandra Boe, Michele Cedrone, Tiziana Ottone, Robin Foà & Ugo Testa. (2009) Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor. British Journal of Haematology 144:3, pages 376-387.
Crossref
Crossref
Robert J. Kreitman. (2009) Recombinant Immunotoxins Containing Truncated Bacterial Toxins for the Treatment of Hematologic Malignancies. BioDrugs 23:1, pages 1-13.
Crossref
Crossref
Arthur E. Frankel, Jung-Hee Woo & David M. Neville. 2009. Principles of Cancer Biotherapy. Principles of Cancer Biotherapy
407
449
.
John E. Dick. (2008) Stem cell concepts renew cancer research. Blood 112:13, pages 4793-4807.
Crossref
Crossref
Henrick Horita, Arthur E. Frankel & Andrew Thorburn. (2008) Acute Myeloid Leukemia-Targeted Toxin Activates Both Apoptotic and Necroptotic Death Mechanisms. PLoS ONE 3:12, pages e3909.
Crossref
Crossref
Jung Hee Woo, Sarah H. Bour, Tony Dang, Yu-Jen Lee, Seong Kyu Park, Elissa Andreas, Soo Hyun Kang, Jen-Sing Liu, David M. NevilleJrJr & Arthur E. Frankel. (2008) Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390–bisFv(UCHT1). Cancer Immunology, Immunotherapy 57:8, pages 1225-1239.
Crossref
Crossref
Stephen D. Nimer. (2008) MDS: A Stem Cell Disorder—But What Exactly Is Wrong with the Primitive Hematopoietic Cells in This Disease?. Hematology 2008:1, pages 43-51.
Crossref
Crossref